Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports outline breast cancer research from C.C. Portera and colleagues
June 26th, 2008
In this recent study, researchers in the United States conducted a study "To evaluate safety and efficacy of trastuzumab with pertuzumab inpatients with human epidermal growth factor receptor 2 (HER2) - positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy. Patients with measurable HER2(+) metastatic breast cancer, <= 3 trastuzumab-based regimens, and left ventricular ejection fraction (LVEF) >= 55% received 8 or 6 mg/kg trastuzumab and 840 mg pertuzumab i.v. followed by 6 mg/kg trastuzumab and 420 mg pertuzumab every 3 weeks." "Cardiac evaluation and tumor response were assessed every 3 and 6 weeks, respectively. Eleven...
Source: Women's Health Weekly (2008-06-26)
|
